TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?

Abstract Patients with chronic lymphocytic leukemia carrying a single TP53 hit (chromosome 17p deletion or single TP53 mutation) demonstrate excellent progression-free survival and overall survival on ibrutinib compared with cases harboring multiple TP53 hits. Testing TP53 deletion/mutation combining FISH and deep next-generation sequencing should be performed for a correct patient evaluation. See related article by Brieghel et al., p. 4531